South Australia to Launch CAR T-Cell Therapy Service at Royal Adelaide Hospital by Mid-2026
核心洞察
South Australia will establish a dedicated CAR T-cell therapy service at Royal Adelaide Hospital by mid-2026, with $2.8 million allocated in the 2025-26 budget for this cutting-edge blood cancer (搜索) treatment.
The service will initially treat four patients in the first year, scaling up over time to reduce the need for approximately 30 South Australian patients who currently travel interstate annually for this specialized therapy.
CAR T-cell therapy involves collecting and genetically modifying a patient's own T-cells (搜索) to target cancer cells (搜索), offering new hope for individuals with hard-to-treat blood cancers including relapsed lymphoma (搜索) and acute lymphoblastic leukemia (搜索).
South Australia will establish its first dedicated CAR T-cell therapy service at the Royal Adelaide Hospital by mid-2026, marking a significant advancement in the state's cancer treatment capabilities. The Malinauskas Labor Government allocated $2.8 million in the 2025-26 budget to lay the foundations of this cutting-edge immunotherapy service as part of the Central Adelaide Local Health Network (搜索) Cancer Program.
Addressing Critical Treatment Gap
The new service will address a significant gap in South Australia's cancer care infrastructure. Currently, approximately 30 patients are sent interstate for CAR T-cell therapy each year, creating substantial logistical and emotional burdens for patients and their families. Health Minister Chris Picton noted that the service would initially treat a small number of patients but would scale up over time, with dozens of people expected to benefit annually, "particularly those patients who have blood cancers where our first-line and even second-line treatments haven't been successful."
The establishment of this service follows advocacy efforts by Adelaide woman Steph Walker, who launched a petition after her father was referred to Melbourne for CAR T-cell therapy. Walker described the challenges faced by immunocompromised patients traveling interstate: "To put an immunocompromised patient on an aeroplane with the general public is super dangerous, let alone the side effects from cancer treatments while being out of home or away from the hospital."
Treatment Process and Technology
CAR T-cell therapy represents a revolutionary approach to treating certain blood cancers, including relapsed lymphoma (搜索) and relapsed acute lymphoblastic leukemia (搜索). The treatment involves collecting a patient's own T-cells (搜索) through a process called leukapheresis, which uses a specialized machine to separate blood components over four to six hours. The isolated T-cells are then transported to a specialized laboratory for genetic modification before being frozen, packaged, and returned to the treatment facility.
During the laboratory processing period, patients undergo chemotherapy. Once the genetically modified CAR T-cells (搜索) are ready, they are infused back into the patient's bloodstream, where they begin to recognize and kill remaining cancer cells (搜索). These CAR T-cells often persist as memory T-cells, providing ongoing protection against potential future relapses.
Clinical Impact and Patient Outcomes
The therapy has demonstrated remarkable efficacy in certain cases. Walker's father, who had undergone three previous stages of cancer treatment including chemotherapy and radiation with only a 20 percent chance of success, achieved complete cancer remission three weeks after CAR T-cell treatment. "He got the treatment and I believe it was a check-up three weeks later, he was completely cancer-free," Walker said.
Adelaide haematologist Pratyush Giri previously described sending critical cancer patients interstate as "suboptimal and risky," noting the assumption that families would be able to help patients live independently for at least a month interstate after hospitalization was "often difficult with elderly patients with little support."
Service Implementation and Infrastructure
The safe delivery of CAR T-cell therapy requires sophisticated infrastructure including specialist equipment for apheresis, cell processing, and infusion capabilities, along with multidisciplinary clinical teams trained in managing immune effector cell therapies and associated toxicities. The Royal Adelaide Hospital service will initially support four patients in the first year, with capacity increasing as the program becomes established.
Central Adelaide Local Health Network (搜索) Cancer Program Director Charlotte Sale emphasized the importance of accessible treatment options: "We are passionate about providing more accessible options for cancer treatment in South Australia, which is why we are working to establish a commercial CAR T-cell therapy service at the Royal Adelaide Hospital."
Broader Cancer Care Strategy
The CAR T-cell service launch coincides with SA Health (搜索)'s appointment of Associate Professor Michael Osborn as the state's first Chief Cancer Officer. Osborn will lead the implementation of the SA Cancer Plan and oversee the recently launched South Australian Comprehensive Cancer Network (SACCaN), which aims to connect clinicians, researchers, and service providers across public, private, and non-government cancer services.
Cancer Australia (搜索) Chief Executive Officer Professor Dorothy Keefe noted that "the establishment of a South Australian CAR T-cell therapy service strongly aligns with the Australian Cancer Plan's vision to ensure equitable access to world class cancer care."
While patients will continue to be supported to travel interstate for treatment during the transition period, with costs covered for public patients, the local service represents a significant step toward comprehensive cancer care accessibility in South Australia. As Minister Picton noted, "This has been an emerging technology over the past few years," and the state's investment reflects growing confidence in the therapy's potential to benefit an aging and growing population facing blood cancer (搜索) diagnoses.